## min read

MTHFR Gene Mutation: What It Means for Mental Health

|

October 17, 2026

Summarize with AI

MTHFR Gene Mutation: What It Means for Mental Health

Maybe a genetic report flagged it. Maybe a friend, a forum, or a supplement ad told you it could explain your fatigue, your depression, or why medication never quite worked. Now you're wondering what an MTHFR gene mutation actually means for you.

MTHFR variants are extremely common. Most people who carry them have no health effects at all, and research linking them to mental health conditions shows a real but small association, not a cause. Medical experts don't recommend routine testing for them.

What the MTHFR gene does

The MTHFR gene carries instructions for an enzyme called methylenetetrahydrofolate reductase. That enzyme converts folate, a B vitamin, into the active form your body uses to turn the amino acid homocysteine into methionine. According to MedlinePlus Genetics, the active form, 5-methyltetrahydrofolate, is the main form of folate found in blood.

When the enzyme works less efficiently, homocysteine can build up. That's the mechanism behind most of the interest in MTHFR, including the mental health questions.

C677T, A1298C, heterozygous, and homozygous

Most people searching "MTHFR gene mutation" are really asking about two common variants:

  • C677T. The most common and best studied. At position 677 in the gene, the DNA base C is replaced by T. The resulting enzyme is less stable and less active, especially in people with two copies.
  • A1298C. The second common variant. The CDC notes there isn't enough evidence that A1298C on its own significantly affects how the body processes folate.

You inherit one copy of the gene from each parent, which is where the lab terms come from:

  • Heterozygous means one copy carries the variant (for C677T, written CT).
  • Homozygous means both copies carry it (TT).
  • Compound heterozygous means one copy of C677T and one copy of A1298C.

These variants are so common they're closer to normal human variation than to a disease. The CDC reports that more people in the U.S. have one or two copies of C677T than don't. Having both copies is less common: MedlinePlus estimates about 25% of Hispanic people and 10% to 15% of North American white people carry two copies of C677T.

MTHFR symptoms: what the variant does and doesn't cause

Most people with common MTHFR variants have no symptoms. Cleveland Clinic puts it plainly: MTHFR gene variants most often don't affect your health or cause symptoms. When they do matter, it's usually through higher homocysteine or lower folate, and mostly in people with two copies of C677T. Even then, how much folate you get from food matters more than your genotype.

That's different from what you'll read on many wellness sites, which attribute everything from fatigue to brain fog to MTHFR. There's no reliable evidence for a list of "MTHFR symptoms" in people with the common variants. If you have symptoms, they deserve an evaluation, not an assumption that a gene variant explains them.

There is one important exception. Rare, severe mutations in the MTHFR gene cause homocystinuria, a serious inherited condition whose symptoms usually appear early in life. Most U.S. newborns are screened for it shortly after birth. That's a different situation from the common C677T and A1298C variants.

MTHFR and mental health: what research shows

Because MTHFR sits in the folate and methylation pathway, researchers have looked hard for links to psychiatric conditions. The findings are consistent in one way: the effect is modest.

  • Depression. A 2013 meta-analysis of 26 studies, with 4,992 people with depression and 17,082 controls, found that two copies of C677T were associated with higher odds of depression (odds ratio 1.42). The link was stronger in Asian populations, marginal in white populations, and absent in older adults.
  • Schizophrenia, bipolar disorder, and depression combined. A 2011 meta-analysis of case-control studies with 29,502 participants found TT carriers had modestly higher odds of these conditions as a group (odds ratio 1.26). The authors read this as evidence of a shared genetic vulnerability across the three conditions.

An odds ratio of 1.26 to 1.42 is a small increase in relative risk for a very common genotype. Most people with two copies of C677T never develop depression, bipolar disorder, or schizophrenia, and most people with those conditions don't have two copies. Mental health conditions come from many genes and life experiences acting together. MTHFR is, at most, one small piece.

Folate, folic acid, and methylfolate

A common online claim is that people with MTHFR variants can't use folic acid and need "methylated" supplements instead. The CDC says that isn't true: people with an MTHFR variant can process all types of folate, including folic acid. People with the TT genotype have blood folate levels only about 16% lower on average than people with CC at the same intake, and folic acid intake matters more than genotype in determining blood folate.

L-methylfolate, the active form, has been studied as an add-on to antidepressants. In two randomized trials published in the American Journal of Psychiatry in 2012, adults with depression that hadn't responded fully to an SSRI received L-methylfolate or placebo alongside their medication. The first trial, with 148 patients starting at 7.5 mg a day, found no difference. The second, with 75 patients at 15 mg a day, found a significant benefit over placebo. Both enrolled people based on their depression, not on a genetic test. Whether any add-on makes sense for a specific person is a clinical decision that depends on their full history.

For more on how folate and other nutrients relate to mood, see our article on nutrient deficiencies and anxiety.

Should you get tested for MTHFR?

For most people, no. MedlinePlus states that medical experts don't recommend testing for common MTHFR gene changes in most cases. A provider may order it in specific situations, such as high homocysteine on a blood test combined with a family history.

The American College of Medical Genetics and Genomics went further in a 2013 practice guideline: MTHFR polymorphism testing has minimal clinical utility and shouldn't be part of a routine evaluation for blood clotting disorders. Recent meta-analyses had disproven the links that originally motivated the testing.

If you already have a result, it's still useful context to share with your care team. It just isn't a diagnosis, and it isn't a treatment plan.

When depression or mood symptoms don't improve

People often look up MTHFR because something isn't working: depression that keeps coming back, medication that only half helps, or mood swings no one has explained. Those problems are real, even if MTHFR is unlikely to be the answer. They usually call for a fuller psychiatric evaluation: a closer look at the diagnosis, past medication trials, co-occurring conditions, sleep, substance use, and physical health.

That's the kind of care we provide at Amae Health. Our clinics specialize in conditions including Major Depressive Disorder, bipolar disorder, and schizophrenia. Our care teams bring psychiatrists, therapists, primary care physicians, and dietitians under one roof, so lab results, nutrition, and medication history are reviewed together, by people who share one treatment plan. See how our integrated outpatient clinics work.

Frequently asked questions

How common is the MTHFR gene mutation?

Very common. According to the CDC, more people in the U.S. have one or two copies of the C677T variant than don't. Two copies are less common, estimated at about 25% of Hispanic people and 10% to 15% of North American white people.

What are the symptoms of being MTHFR C677T heterozygous?

Usually none. According to MedlinePlus, raised homocysteine is seen mainly in people with two copies of C677T. If you have symptoms, they need an evaluation of their own rather than being attributed to one copy of a common variant.

Does MTHFR cause depression?

No single gene causes depression. Two copies of C677T are associated with modestly higher odds of depression in meta-analyses, with an odds ratio around 1.4, but most people who carry them never develop depression.

Do people with MTHFR need methylfolate instead of folic acid?

According to the CDC, no. People with MTHFR variants can process folic acid, and folic acid intake matters more than genotype for blood folate levels. L-methylfolate has been studied as an add-on treatment for depression, regardless of MTHFR status, and decisions about it belong with a clinician.

Is MTHFR testing worth it?

For most people, it isn't recommended. Medical genetics experts say the common variants have minimal clinical utility. A provider may order testing in specific cases, such as unexplained high homocysteine with a family history.

Key takeaways

  • An MTHFR gene mutation usually means one or two copies of the common C677T or A1298C variants, which most people carry without health effects.
  • Two copies of C677T can raise homocysteine and are linked to modestly higher odds of depression, bipolar disorder, and schizophrenia, but the effect is small.
  • People with MTHFR variants can process folic acid, and routine MTHFR testing isn't recommended.
  • If depression or mood symptoms aren't improving, a full psychiatric evaluation is more useful than a gene result.

If you or someone you love is living with depression, bipolar disorder, or schizophrenia that hasn't responded to treatment, request an intake appointment. Our team will walk you through how an evaluation works and what to bring, including any lab or genetic results you already have.

Reccomended for you

# min read

What is the Best Treatment for Schizophrenia?

By

Sonia Garcia

|

October 28, 2026

When someone you love is diagnosed with schizophrenia, the first questions usually come fast. What actually works? Is there a cure? Will they be on medication forever? The answer is more hopeful than many families expect, and more complicated than a single "best" option.

The best treatment for schizophrenia isn't one medication or one therapy. It's a combination: antipsychotic medication to reduce psychotic symptoms, psychosocial treatments to rebuild daily life, support for the family, and, for people early in the illness, a coordinated team that brings all of it together. Treatment works best when it starts early and continues over time.

Can schizophrenia be cured?

There's no cure for schizophrenia in the sense of a treatment that makes it disappear permanently. But recovery is possible, and more common than many people realize. According to the WHO, at least one in three people with schizophrenia will be able to fully recover.

The goal of treatment, as the NIMH describes it, is to help people manage their symptoms, improve day-to-day functioning, and reach personal goals such as finishing school, working, and having fulfilling relationships.

People often search for "how to cure schizophrenia permanently." Be wary of any program, supplement, or provider that promises a permanent cure. The approaches below are the ones with evidence behind them.

Antipsychotic medication

Antipsychotics are the foundation of treatment for most people with schizophrenia. According to the NIMH, they can make psychotic symptoms such as hallucinations and delusions less intense and less frequent. Most are taken daily as a pill or liquid. Some come as an injection given once or twice a month.

Is there a "best" medication for schizophrenia?

No single antipsychotic is best for everyone. People respond differently, and the NIMH notes that some people need to try several medications before finding the one that works best for them.

The bigger differences between antipsychotics are often in side effects. The NIMH lists weight gain, dry mouth, restlessness, and drowsiness as common early side effects. A 2020 network meta-analysis in The Lancet Psychiatry of 100 trials and 25,952 patients compared 18 antipsychotics and found large differences in their effects on weight, cholesterol, and blood sugar. Clozapine and olanzapine were among those with the largest metabolic changes. That's one reason medication choice is individual, and why physical health monitoring matters during treatment.

The NIMH also advises against stopping an antipsychotic without talking to a health care provider first, so that changes can be made safely.

Clozapine for treatment-resistant schizophrenia

When symptoms don't improve with usual antipsychotics, the NIMH notes that clozapine may be prescribed. People taking clozapine need regular blood tests to check for a potentially dangerous side effect that occurs in 1% to 2% of patients.

Long-acting injectable antipsychotics

Long-acting injectables (LAIs) are given every few weeks or months rather than taken daily. A 2021 meta-analysis in The Lancet Psychiatry of 137 studies with nearly 400,000 patients found that LAIs were associated with a lower risk of hospitalization or relapse than oral antipsychotics across randomized trials, cohort studies, and before-and-after studies. The difference was modest in randomized trials and larger in real-world data.

Psychosocial treatments

Medication reduces psychotic symptoms. It doesn't, on its own, rebuild a life. According to the NIMH, people who take part in regular psychosocial treatment are less likely to have symptoms come back or to be hospitalized. Examples include:

  • Cognitive behavioral therapy (CBT): helps people work with distressing beliefs and voices and build coping strategies
  • Behavioral skills training: builds social and daily living skills
  • Supported employment: helps people find and keep jobs
  • Cognitive remediation: targets attention, memory, and problem-solving, which the NIMH notes are among the best predictors of day-to-day functioning

Family education and support

Schizophrenia affects the whole family. The NIMH notes that educational programs help family and friends understand symptoms and treatment options, manage their own distress, and support their loved one more effectively.

Treatment for co-occurring substance use

Many people with schizophrenia also use drugs or alcohol. The NIMH emphasizes that treating both together matters, because substance use can interfere with treatment for schizophrenia.

Coordinated specialty care for early psychosis

For people early in the illness, coordinated specialty care (CSC) is the model with the strongest support. It's a team approach for first-episode psychosis that combines psychotherapy, medication, case management, employment and education services, and family education and support, with the person involved in every treatment decision. According to the NIMH, compared with typical care, CSC is more effective in reducing symptoms, improving quality of life, and increasing involvement in work or school.

For people who are likely to face repeated hospitalizations or homelessness, assertive community treatment brings a team of providers to the person in the community.

Why early treatment matters

Timing changes outcomes. The NIMH notes that people with psychosis often have symptoms for more than a year before getting treatment, and that early treatment often means better recovery. If you're seeing early warning signs, such as withdrawal, suspiciousness, or a drop in functioning, an evaluation shouldn't wait. Our article on psychosis vs. schizophrenia covers those signs in more detail.

How we treat schizophrenia at Amae Health

Schizophrenia, schizoaffective disorder, and first-episode psychosis are among the conditions our clinics specialize in. Our care teams bring psychiatrists, therapists, primary care physicians, dietitians, peer mentors, and care coordinators under one roof, working from one treatment plan. That means medication, therapy, physical health, and practical support are handled together. For people who need more than weekly care, we offer an Intensive Outpatient Program (IOP) and a Partial Hospitalization Program (PHP). For a broader overview, see schizophrenia treatment options.

Frequently asked questions

Can schizophrenia be cured?

There's no permanent cure, but recovery is possible. The WHO reports that at least one in three people with schizophrenia will be able to fully recover, and treatment aims to help people manage symptoms and reach their personal goals.

What is the first-line treatment for schizophrenia?

Antipsychotic medication is the foundation, usually combined with psychosocial treatments such as CBT, skills training, and family education. For first-episode psychosis, coordinated specialty care brings these together in one team.

What is the best medication for schizophrenia?

There isn't one best medication for everyone. Antipsychotics differ mainly in side effects, and people often try more than one before finding the right fit. Clozapine is used when other antipsychotics haven't worked, and long-acting injectables offer an alternative to a daily pill.

Will someone with schizophrenia need medication forever?

Schizophrenia usually requires ongoing treatment, and the right plan depends on the person's history and response. Decisions about changing or stopping medication should always be made with a health care provider, never alone.

Can schizophrenia be treated without medication?

Psychosocial treatments are essential, but for most people they work alongside medication rather than replacing it. The trade-offs are different for every person and belong in a conversation with their care team.

Key takeaways

  • The best treatment for schizophrenia combines antipsychotic medication, psychosocial treatments, and family support.
  • No single antipsychotic is best for everyone. Side effects differ widely, and clozapine helps when others don't.
  • Long-acting injectables are associated with fewer relapses and hospitalizations than daily pills.
  • Coordinated specialty care is the standard for first-episode psychosis, and early treatment leads to better recovery.
  • There's no cure, but at least one in three people with schizophrenia fully recover.

If you or someone you love is living with schizophrenia or showing early signs of psychosis, request an intake appointment. Our team will explain how an evaluation works and what to expect from the first visit.

# min read

Can You Be Hospitalized for Anxiety?

By

Sonia Garcia

|

October 29, 2026

Your heart is racing, your chest is tight, and you can't tell whether this is panic or something worse. Or maybe the anxiety has gone on for weeks and you've stopped sleeping, eating, or leaving the house. Either way, you're wondering whether this is something a hospital can help with.

Yes, you can go to the hospital for anxiety, and sometimes you should. An emergency room is the right place when you can't rule out a medical emergency, or when anxiety comes with thoughts of suicide or makes it impossible to stay safe. Being admitted to a psychiatric unit for anxiety alone is less common. For severe anxiety that isn't an emergency, structured outpatient programs are often the better fit.

If you're thinking about suicide or hurting yourself, call or text 988 now, or call 911.

Can you go to the ER for a panic attack?

Yes. Panic attacks can feel exactly like a heart attack. According to MedlinePlus, symptoms can include chest pain, a pounding heart, shortness of breath, dizziness, numbness or tingling, and fear of dying, and many people with panic disorder first seek treatment in the emergency room for exactly that reason.

You can't reliably tell the difference on your own, so don't try. MedlinePlus advises calling 911 for chest pain that feels like sudden crushing, squeezing, or pressure, pain that spreads to the jaw, left arm, or between the shoulder blades, or chest pain with nausea, dizziness, sweating, a racing heart, or shortness of breath. Being told it was "only" panic is a good outcome, not a wasted trip.

What happens at the hospital for anxiety?

In the ER, the first job is to rule out a medical cause. MedlinePlus notes that a provider will do a physical exam and a mental health assessment, and may order blood tests, because other medical problems need to be checked before panic disorder can be diagnosed.

People often search "what do they give you at the hospital for anxiety." If symptoms are severe, ER staff may use a short-acting anti-anxiety medication. The NIMH notes that benzodiazepines are useful for short-term relief of severe anxiety but can lead to tolerance or dependence over long periods, which is why they're generally used briefly. After the evaluation, the ER team decides whether someone can go home with a follow-up plan or needs more care.

When does anxiety need hospitalization?

Admission to a psychiatric unit is usually reserved for situations where someone isn't safe or can't be treated effectively outside a hospital. With anxiety, that typically means:

  • Thoughts of suicide or self-harm, especially with a plan or intent
  • Severe depression alongside anxiety, particularly when it stops someone from eating, sleeping, or caring for themselves
  • Inability to function or stay safe, such as not eating or drinking enough
  • Psychotic symptoms, such as hearing voices or holding beliefs others don't share
  • Severe substance use or withdrawal tangled up with the anxiety

Panic attacks on their own, however frightening, usually don't require admission once medical causes have been ruled out.

What a psychiatric hospital stay looks like

Stays are usually short. A federal analysis of U.S. hospital data found that in 2016, hospital stays principally for mental and substance use disorders averaged 6.4 days. The focus is on safety, stabilizing symptoms, adjusting medication, and planning what happens after discharge. We explain the difference between settings in psych ward vs. mental hospital.

Voluntary and involuntary admission

Many people are admitted voluntarily. Involuntary admission is generally reserved for situations where someone is a danger to themselves or others and won't accept care, and the rules are set by each state.

Options between weekly therapy and a hospital

For many people with severe anxiety, the gap isn't between "fine" and "hospital." It's between a weekly appointment that isn't enough and a hospital stay that isn't necessary. Structured outpatient programs fill that gap:

These programs are also a common step down after a hospital stay. See PHP vs. IOP for a side-by-side comparison.

How anxiety is treated long term

For most people, treatment happens outside the hospital. According to the NIMH, antidepressants such as SSRIs and SNRIs are commonly used for anxiety disorders, and health care providers typically start with them for panic disorder and social anxiety disorder. Talk therapy is the other core part of treatment. MedlinePlus notes that while panic disorder can be long-lasting, most people get better when treated correctly.

Where Amae Health fits

We aren't a hospital. Amae Health runs outpatient clinics with PHP and IOP programs. Our clinics specialize in severe mental illness, including Major Depressive Disorder, bipolar disorder, and suicidal thoughts and attempts, and anxiety often comes with these conditions. Our care teams bring psychiatrists, therapists, primary care physicians, and care coordinators under one roof, working from one treatment plan.

Frequently asked questions

Can you be hospitalized for anxiety?

Yes. People can be admitted when anxiety comes with suicidal thoughts, severe depression, psychosis, or an inability to stay safe or function. Admission for anxiety alone is less common, and many people with severe anxiety are treated in intensive outpatient programs instead.

Should I go to the hospital for a panic attack?

If you have chest pain, trouble breathing, or symptoms you can't explain, go to the ER or call 911. Panic attacks can mimic a heart attack, and only a medical evaluation can rule that out.

What do they give you at the hospital for anxiety?

After checking for medical causes, ER staff may use a short-acting anti-anxiety medication for severe symptoms. These medications are meant for short-term use. The ER team then decides whether you can go home with a follow-up plan or need more care.

How long do you stay in the hospital for anxiety?

Psychiatric hospital stays are usually short. In U.S. data from 2016, stays for mental and substance use disorders averaged 6.4 days.

When should I go to the ER for anxiety?

Go if you have chest pain or other symptoms that could be a medical emergency, if you're thinking about suicide or self-harm, or if you can't stay safe or care for yourself. For suicidal thoughts, you can also call or text 988.

Key takeaways

  • You can go to the ER for anxiety or a panic attack, especially with chest pain, which should always be checked.
  • Psychiatric admission for anxiety alone is less common and usually involves safety concerns, severe depression, or psychosis.
  • Hospital stays are short, about 6.4 days on average for mental health conditions.
  • Intensive outpatient and partial hospitalization programs fill the gap between weekly therapy and the hospital.

If anxiety comes with depression, mood swings, or thoughts of suicide, and weekly appointments aren't enough, request an intake appointment. Our team will explain how PHP and IOP work and what to expect from the first visit.

# min read

Spravato Success Rate: Does It Work, and for Whom?

By

Sonia Garcia

|

October 26, 2026

Spravato success rate figures are easy to find and hard to compare. In the trial that supported its FDA approval, 69.3% of people who finished 4 weeks of Spravato with a new antidepressant had responded, and 52.5% were in remission. A study of routine care in Italy found 64.2% response and 40.6% remission at 3 months. The numbers answer slightly different questions, but they agree on the essentials: Spravato helps many people with treatment-resistant depression, response is more common than remission, and no single percentage tells the whole story.

Spravato also leaves a real share of people without enough relief.

Spravato is the brand name for esketamine, a nasal spray FDA-approved for treatment-resistant depression: depression that hasn't responded adequately to at least two antidepressants, each given at a proper dose for long enough.

What "Success" Means: Response vs. Remission

Nearly every Spravato statistic comes from one yardstick, the Montgomery-Åsberg Depression Rating Scale (MADRS). It's a 10-item interview a clinician scores from 0 to 60, where higher means more severe, and people entering Spravato's main approval trial averaged about 37. Two thresholds turn that score into a success rate:

  • Response means the MADRS score has fallen by at least half from where it started.
  • Remission means the score has dropped to 12 or lower, the cutoff the Spravato trials used.

The distance between the two is wide. Someone who starts at 38 and falls to 19 counts as a responder and may still have symptoms that get in the way of work, sleep, or relationships. Remission is the fuller recovery and the harder bar, so every remission figure below sits under its response figure.

Spravato's Success Rate in the Trial Behind Its Approval

The short-term trial that supported FDA approval was TRANSFORM-2, published in The American Journal of Psychiatry in 2019. Researchers at 39 outpatient centers enrolled adults with moderate to severe depression who hadn't responded to at least two antidepressants in their current episode. Everyone switched to a new oral antidepressant. One group also received Spravato, 56 or 84 mg twice a week, and the other a placebo spray. Of 227 people randomized, 197 finished the 4-week double-blind phase, and MADRS scores in the Spravato group fell 4 points more, on average.

The European Medicines Agency's review of the trial data translates that into response and remission:

At day 28 Spravato + new antidepressant Placebo spray + new antidepressant
Response, people who completed 4 weeks 69.3% 52.0%
Remission, people who completed 4 weeks 52.5% 31.0%
Response, including people who left early 63.4% 49.5%
Remission, including people who left early 48.2% 30.3%

Look first at the comparison group: more than half of the people who started a new antidepressant with a placebo spray also responded. The trial's finding is the gap. Among people who completed 4 weeks, adding Spravato meant about 17 more responders and 21 more remitters in every 100.

The counting method matters too, and it explains much of the inconsistency online. Figures near 69% count only people who finished. Figures near 63% for response, or 48% for remission, carry forward the last score of everyone who stopped early.

Real-World Success Rates

Trials select their patients carefully and follow them for weeks. Routine care is messier, which is what makes REAL-ESK useful. That 2022 study, published in the Journal of Affective Disorders, reviewed the medical records of 116 people with treatment-resistant depression treated with Spravato at several Italian mental health services, with assessments at 1 and 3 months.

By 3 months, 64.2% had responded and 40.6% were in remission, and both rates had climbed sharply between the first month and the third. The authors called that later response one of the study's novel findings. They also found no difference in effectiveness between people with other psychiatric conditions and people without them.

Lining those numbers up against TRANSFORM-2 doesn't work cleanly. REAL-ESK had no placebo or comparison group, everyone knew they were receiving Spravato, ratings weren't checked for consistency across centers, and 3 months is a different finish line from 4 weeks. It's encouraging evidence from everyday practice, not a controlled measure of effect.

Who Spravato Is Approved and Studied For

Spravato has two FDA-approved uses, built on separate trials, according to its prescribing information:

  • Treatment-resistant depression in adults, on its own or with an oral antidepressant. The original 2019 approval required an oral antidepressant alongside it; standalone use was added in January 2025.
  • Depression with acute suicidal thoughts or behavior, in adults with major depressive disorder, given alongside an oral antidepressant to treat the depressive symptoms.

The second use came from trials of a different group: adults with moderate to severe depression and active suicidal thoughts with intent, all of whom began with an inpatient psychiatric stay and standard care, and 63% of whom had attempted suicide before. Those results shouldn't be mixed with the treatment-resistant depression results.

The label is explicit about one boundary. Spravato hasn't been shown to prevent suicide or to reduce suicidal thoughts or behavior, and it doesn't replace hospitalization when that's needed, even if someone feels better after the first dose. It isn't approved for children. If suicidal thoughts are part of what you're living with right now, care for suicidal thoughts comes first, and 988 answers calls and texts at any hour.

How Fast Results Typically Appear

Spravato's reputation for speed comes from the first day. In TRANSFORM-2, most of the difference from placebo was already visible at 24 hours, the label reports; both groups kept improving through day 28, and the gap held steady rather than widening. The monotherapy trial behind the 2025 approval showed an effect at about 24 hours that lasted through day 28. In the suicidal-thoughts trials, the difference appeared as early as 4 hours.

Early movement isn't the same as response. In TRANSFORM-2, only 7.9% of people on Spravato had a response that began by day 2 and held through day 28, compared with 4.6% on placebo spray, a difference that wasn't statistically significant in the EMA review. The label calls for judging benefit at the end of the 4-week induction phase, after which sessions drop from twice a week to weekly.

And as REAL-ESK suggests, for some people even 4 weeks is early.

What Affects Individual Success

Research points to a handful of factors linked to outcomes, none of them a forecast for any one person:

  • Time on treatment. Benefit is formally assessed after the 4-week induction phase, and in REAL-ESK, many responses and remissions arrived between the first and third month.
  • Continuing after a good response. In a maintenance study described in the label, people in stable remission who kept taking Spravato went significantly longer before relapsing than people switched to a placebo spray, and the same held for people in stable response.
  • Age. The evidence is weaker in older adults. In a separate short-term trial of adults 65 and older, response at day 28 was 27.0% with Spravato versus 13.3% with placebo spray, and the trial's main measure narrowly missed statistical significance, per the EMA review.
  • Other psychiatric conditions. REAL-ESK found people with additional psychiatric diagnoses did as well as people without them.
  • With or without an oral antidepressant. Spravato has shown benefit both ways, but no trial in the label compared the two head to head.

Limits and Risks

The same data show where Spravato falls short.

  • Many people don't reach remission. Nearly half of the people who completed TRANSFORM-2 on Spravato weren't in remission at day 28, and in REAL-ESK, about six in 10 weren't in remission at 3 months.
  • Not every trial was positive. Of the three short-term trials submitted for approval, only TRANSFORM-2 met its main goal. A fixed-dose trial in adults and the trial in older adults both fell short of statistical significance, according to the EMA review.
  • It carries a boxed warning for sedation, dissociation, breathing problems (respiratory depression), and misuse or abuse, plus the risk of suicidal thoughts and behaviors that antidepressants carry for children and young adults. Sedation showed up in 48% to 61% of trial participants on Spravato, and dissociation, a sense of detachment that can warp time, space, or surroundings, in 61% to 84%.

Those risks shape how Spravato is given. It's only available through a restricted program called the Spravato REMS. You use the spray yourself under supervision in a certified healthcare setting, your blood pressure is checked before and after, and you're monitored for at least 2 hours before you're cleared to leave. Driving is off-limits until the next day, after a night of restful sleep. People with certain blood vessel problems, including an aneurysm, an abnormal connection between arteries and veins, or past bleeding in the brain, can't take it at all.

Talking to a Psychiatrist About Your Options

A Spravato success rate is a group statistic. It shows that Spravato helps a substantial share of people with treatment-resistant depression and that remission is harder to reach than response. It can't tell you what will happen for you. That depends on your diagnosis, what you've tried and for how long, your medical history, and the rest of your care.

We don't offer Spravato at Amae. Major depressive disorder is among the conditions our clinics specialize in, and when it hasn't eased with medication, our psychiatrists treat it within our integrated care model, which puts psychiatry, medication management, therapy, and primary care on one team. TMS therapy runs at three of our clinics: Los Angeles, Los Altos, and San Mateo. Our comparison of TMS, ketamine, and Spravato and our look at TMS success rates lay out how those options differ. To go over your history with someone who can see all of it, schedule an evaluation with an Amae psychiatrist. Anyone in immediate danger should call 911.

Frequently Asked Questions

What is Spravato's success rate in clinical trials?

In TRANSFORM-2, the short-term trial behind FDA approval, 69.3% of people who completed 4 weeks of Spravato plus a new antidepressant responded and 52.5% reached remission, versus 52.0% and 31.0% with a placebo spray plus a new antidepressant. Counting people who left early, remission was 48.2% versus 30.3%.

Does Spravato work better in real-world use than in trials?

The figures look similar, but they can't be compared directly. REAL-ESK, a study of 116 people treated in routine care in Italy, found 64.2% response and 40.6% remission at 3 months, with no placebo group and a longer follow-up than the 4-week trials.

How fast does Spravato start working?

Average scores often pull ahead of placebo within 24 hours, and in trials of people with suicidal thoughts, within 4 hours. A lasting response that early is uncommon, so benefit is judged after the 4-week induction phase, and some people improve later still.

Does Spravato work for everyone?

No. In TRANSFORM-2, nearly a third of people who completed treatment didn't respond, and nearly half didn't reach remission. Two other short-term trials, including one in adults 65 and older, didn't reach statistical significance on their main measure.

What happens if Spravato doesn't work for me?

A psychiatrist looks at the whole picture again: the diagnosis, whether treatment ran long enough, other medications, and other conditions. Next steps might include a different medication strategy, adding or changing therapy, or another treatment for treatment-resistant depression, such as TMS or ECT.

Is Spravato's success rate different for suicidal depression versus treatment-resistant depression?

Yes, and the two shouldn't be blended. The suicidal-thoughts trials measured average score changes 24 hours after the first dose in hospitalized adults receiving standard care. Spravato lowered depression scores more than placebo, but it didn't improve a rating of suicidality more than placebo, and it hasn't been shown to reduce suicidal thoughts.

Citations

  1. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. The American Journal of Psychiatry. 2019;176(6):428-438. https://pubmed.ncbi.nlm.nih.gov/31109201/ (Tier 1)
  2. European Medicines Agency. Spravato: EPAR public assessment report (EMA/614876/2019). 2019. https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf (Tier 2, regulatory review)
  3. Martinotti G, Vita A, Fagiolini A, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). Journal of Affective Disorders. 2022;319:646-654. https://pubmed.ncbi.nlm.nih.gov/36167246/ (Tier 1)
  4. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised April 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf (Tier 2)
  5. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)